研究疾病:
|
急性冠状动脉综合征
|
研究疾病代码:
|
|
Target disease:
|
Acute Coronary Syndrome
|
Target disease code:
|
研究类型:
Study type:
|
观察性研究
Observational study
|
研究设计:
Study design:
|
队列研究
Cohort study
|
研究所处阶段:
Study phase:
|
上市后药物
Post-marketing clinical trial
|
研究目的:
|
本研究利用胸痛中心体系建设及平台优势,结合胸痛中心模式的ACS规范化诊疗体系,通过多中心、大样本、真实世界研究,择院前120/基层医院/急诊科的ACS患者为研究对象,对速效救心丸在ACS患者院前临床实际运用过程中的效果进行观察,评价速效救心丸在社会公众/院前120/基层医院/急诊科对于ACS患者的临床疗效和安全性,揭示早期应用速效救心丸对ACS的治疗作用;完成高质量研究2800例,建立数据库;撰写及投稿核心期刊论文1篇;为临床上推广中西医结合方案治疗ACS提供科学依据,指导临床合理使用中药,并提供安全信息。
|
Objectives of Study:
|
This study utilizes the advantages of the chest pain center system construction and platform, combined with the standardized diagnosis and treatment system of ACS based on the chest pain center model. Through multi center, large sample, real-world research, ACS patients in the pre hospital 120/primary hospital/emergency department were selected as the research objects to observe the effectiveness of the quick acting heart saving pill in the pre hospital clinical application process of ACS patients, evaluate the clinical efficacy and safety of the quick acting heart saving pill in the public/pre hospital 120/primary hospital/emergency department for ACS patients, and reveal the therapeutic effect of early application of the quick acting heart saving pill on ACS; Completed 2800 high-quality studies and established a database; Write and submit one core journal paper; To provide scientific basis for promoting the integration of traditional Chinese and Western medicine in the treatment of ACS in clinical practice, guide the rational use of traditional Chinese medicine in clinical practice, and provide safety information.
|
药物成份或治疗方案详述:
|
速效救心丸由川芎、冰片组成,行气活血,祛瘀止痛,用于气滞血瘀型冠心病,心绞痛的治疗。相关研究表明,速效救心丸在改善循环、抗动脉粥样硬化、促进血管新生及心肌增殖和抗缺血再灌注损伤方面作用明显。速效救心丸主要用于治疗稳定型心绞痛、ACS、冠脉临界病变、经冠状动脉介入术(Percutaneous coronary intervention,PCI)围手术期等心血管疾病,可改善临床症状,增加心肌血氧供应,降低主要不良心血管事件(Major adverse cardiovascular events,MACE)事件发生率,改善预后,并对心律失常、高血压、糖尿病等合并其他疾病有临床疗效。其中,对于速效救心丸治疗ACS的临床研究,主要围绕缓解ACS患者的临床症状、提高心电图疗效、降低临床终点事件的发生率和改善预后方面,相关基础研究主要涉及改善血液流变学、抗炎、改善心功能等方面,存在对于主流指标及病例数量观察时间短、观察基数小等问题。
|
Description for medicine or protocol of treatment in detail:
|
This study utilizes the advantages of the chest pain center system construction and platform, combined with the standardized diagnosis and treatment system of ACS based on the chest pain center model. Through multi center, large sample, real-world research, ACS patients in the pre hospital 120/primary hospital/emergency department were selected as the research objects to observe the effectiveness of the Suxiao Jiuxin pill in the pre hospital clinical application process of ACS patients, evaluate the clinical efficacy and safety of the Suxiao Jiuxin pill in the public/pre hospital 120/primary hospital/emergency department for ACS patients, and reveal the therapeutic effect of early application of the Suxiao Jiuxin pill on ACS; Completed 2800 high-quality studies and established a database; Write and submit one core journal paper; To provide scientific basis for promoting the integration of traditional Chinese and Western medicine in the treatment of ACS in clinical practice, guide the rational use of traditional Chinese medicine in clinical practice, and provide safety information.
|
纳入标准:
|
①院前120/基层医院/急诊科患者;
②符合西医ACS诊断标准;
③性别不限,病程不限。
|
Inclusion criteria
|
① 120 patients/primary hospital/emergency department;
② Meets the diagnostic criteria for ACS in Western points;
③ Gender not limited, duration of illness not limited,.
|
排除标准:
|
①症状较重但控制效果较差的患者,如诊断为心力衰竭、心肌病、心肌炎、严重代谢性疾病、恶性肿瘤、严重肝功能衰竭或肾功能衰竭等的患者;
②有认知功能障碍或是诊断为精神病的患者;
③患者为过敏体质,或明确对该研究的治疗药物过敏的患者;
④依从性差或是将会不能按计划参加访视的患者;
⑤研究者认为有不适宜参与该试验的除上述之外的可能情况;
⑥急性下壁、右室心肌梗死禁用硝酸甘油。
|
Exclusion criteria:
|
① Patients with severe symptoms but poor control effects, such as those diagnosed with heart failure, cardiomyopathy, myocarditis, severe metabolic diseases, malignant tumors, severe liver failure, or renal failure;
② Patients with cognitive impairment or diagnosed with mental illness;
③ The patient has an allergic constitution or is clearly allergic to the treatment drug studied in this study;
④ Patients with poor compliance or who may not be able to attend the visit as planned;
⑤ The researchers believe that there may be situations other than those mentioned above that are not suitable for participating in the experiment;
⑥ Nitroglycerin is contraindicated for acute inferior wall and right ventricular myocardial infarction.
|
研究实施时间:
Study execute time:
|
从From
2024-01-30
至To
2025-12-30
|
征募观察对象时间:
Recruiting time:
|
从From
2024-05-13
至To
2025-07-30
|